Lindis Bloodcare GmbH, of Hennigsdorf, Germany, received funding from High-Tech Gründerfonds, Brandenburg Kapital and five private investors. Including €3.3 million (US$3.68 million) in grants from the ProFIT program of the European Regional Development Fund, the company received a total of more than €5 million (US$5.57 million). The funds will be used to advance the clinical development of Catuvab, which is designed to enable tumor cell free return of autologous blood collected during a surgery without significantly altering standard surgical procedures.
Notal Vision Inc., an ophthalmic diagnostic services company based in Manassas, Va., said it secured $25 million in a funding round led by Ganot Capital. The investment will enable Notal to support the commercial growth of its Foreseehome AMD monitoring program as well as further research and development efforts for pipeline technologies.
Orthopediatrics Corp., a Warsaw, Ind.-based developer of orthopedic implants for children, reported the pricing of its underwritten public offering of 1.57 million shares of its common stock at a price of $36.50 per share. 1.52 million of the shares are being offered by the company, and 50,000 shares are being offered by certain selling stockholders. Orthopediatrics will not receive any proceeds from the sale of the shares by the selling stockholders. The offering is expected to close Dec. 13. The company has granted the underwriters a 30-day option to purchase up to an additional 235,500 shares of its common stock. Piper Jaffray and Stifel are acting as joint book-running managers and BTIG, JMP Securities and Suntrust Robinson Humphrey are acting as co-managers of the proposed offering. Orthopediatrics intends to use the proceeds to invest in implant and instrument sets for consignment to its customers, funding research and development activities, expanding its sales and marketing programs, and working capital and general corporate purposes.